The transcriptional modulator HMGA2 promotes stemness and tumorigenicity in glioblastoma
Glioblastoma (GBM) contains a population of stem-like cells that promote tumor invasion and resistance to therapy. Identifying and targeting stem cell factors in GBM may lead to the development of more effective therapies. High Mobility Group AT-hook 2 (HMGA2) is a transcriptional modulator that mediates motility and self-renewal in normal and cancer stem cells. We identified increased expression of HMGA2 in the majority of primary human GBM tumors and cell lines compared to normal brain. Additionally, HMGA2 expression was increased in CD133+ GBM neurosphere cells compared to CD133- cells. Targeting HMGA2 with lentiviral short hairpin RNA (shRNA) led to decreased GBM stemness, invasion, and tumorigenicity. Ectopic expression of HMGA2 in GBM cell lines promoted stemness, invasion, and tumorigenicity. Our data suggests that targeting HMGA2 in GBM may be therapeutically beneficial..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:377 |
|---|---|
| Enthalten in: |
Cancer letters - 377(2016), 1, Seite 55-64 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kaur, Harpreet [VerfasserIn] |
|---|
| Links: |
Volltext |
|---|
| Themen: |
Binding sites |
|---|
| doi: |
10.1016/j.canlet.2016.04.020 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1978806876 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1978806876 | ||
| 003 | DE-627 | ||
| 005 | 20230510064325.0 | ||
| 007 | tu | ||
| 008 | 160720s2016 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.canlet.2016.04.020 |2 doi | |
| 028 | 5 | 2 | |a PQ20161012 |
| 035 | |a (DE-627)OLC1978806876 | ||
| 035 | |a (DE-599)GBVOLC1978806876 | ||
| 035 | |a (PRQ)c2167-6657f6038413bef0cd6bc774e808ac887a88c24a92ecdb1d86346b3a474b2ab40 | ||
| 035 | |a (KEY)0019274020160000377000100055transcriptionalmodulatorhmga2promotesstemnessandtu | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 570 |q DNB |
| 084 | |a BIODIV |2 fid | ||
| 100 | 1 | |a Kaur, Harpreet |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The transcriptional modulator HMGA2 promotes stemness and tumorigenicity in glioblastoma |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Glioblastoma (GBM) contains a population of stem-like cells that promote tumor invasion and resistance to therapy. Identifying and targeting stem cell factors in GBM may lead to the development of more effective therapies. High Mobility Group AT-hook 2 (HMGA2) is a transcriptional modulator that mediates motility and self-renewal in normal and cancer stem cells. We identified increased expression of HMGA2 in the majority of primary human GBM tumors and cell lines compared to normal brain. Additionally, HMGA2 expression was increased in CD133+ GBM neurosphere cells compared to CD133- cells. Targeting HMGA2 with lentiviral short hairpin RNA (shRNA) led to decreased GBM stemness, invasion, and tumorigenicity. Ectopic expression of HMGA2 in GBM cell lines promoted stemness, invasion, and tumorigenicity. Our data suggests that targeting HMGA2 in GBM may be therapeutically beneficial. | ||
| 540 | |a Nutzungsrecht: © Elsevier Ireland Ltd | ||
| 540 | |a Copyright © 2016 Elsevier Ireland Ltd. All rights reserved. | ||
| 650 | 4 | |a Brain cancer | |
| 650 | 4 | |a Genes | |
| 650 | 4 | |a Brain research | |
| 650 | 4 | |a MicroRNAs | |
| 650 | 4 | |a Cancer therapies | |
| 650 | 4 | |a Pediatrics | |
| 650 | 4 | |a Medical research | |
| 650 | 4 | |a Binding sites | |
| 650 | 4 | |a Deoxyribonucleic acid--DNA | |
| 650 | 4 | |a Medical prognosis | |
| 650 | 4 | |a Epidermal growth factor | |
| 650 | 4 | |a Cancer | |
| 700 | 1 | |a Ali, Sabeen Zulfiqar |4 oth | |
| 700 | 1 | |a Huey, Lauren |4 oth | |
| 700 | 1 | |a Hütt-Cabezas, Marianne |4 oth | |
| 700 | 1 | |a Taylor, Isabella |4 oth | |
| 700 | 1 | |a Mao, Xing-gang |4 oth | |
| 700 | 1 | |a Weingart, Melanie |4 oth | |
| 700 | 1 | |a Chu, Qian |4 oth | |
| 700 | 1 | |a Rodriguez, Fausto J |4 oth | |
| 700 | 1 | |a Eberhart, Charles G |4 oth | |
| 700 | 1 | |a Raabe, Eric H |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer letters |d Amsterdam : Elsevier, 1975 |g 377(2016), 1, Seite 55-64 |w (DE-627)166458880 |w (DE-600)195674-7 |w (DE-576)01481272X |x 0304-3835 |7 nnns |
| 773 | 1 | 8 | |g volume:377 |g year:2016 |g number:1 |g pages:55-64 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1016/j.canlet.2016.04.020 |3 Volltext |
| 856 | 4 | 2 | |u http://www.sciencedirect.com/science/article/pii/S0304383516302555 |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/27102002 |
| 856 | 4 | 2 | |u http://search.proquest.com/docview/1790153199 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-BIODIV | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_4219 | ||
| 951 | |a AR | ||
| 952 | |d 377 |j 2016 |e 1 |h 55-64 | ||